KA/EN
Register
Medicines reference
Search
Search
Product

ADOCAM

Favourites

Meloxicam · aniMedica Herstellungs GmbH

1 form: suspension. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Suspension · Dog Dog Loading · By mouth: 0.2 mg/kgMaintenance · By mouth: 0.1 mg/kg - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ადოკამი 1.5 მგ/მლ
№ 300-11; 320-11; 321-11
Verified on: 20 Oct 2026
Details: pack, label wording, sources, registration

ADOCAM, Suspension

Meloxicam 1.5 mg/ml oral suspension for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
7.9/10
Good
vetman assessment

ADOCAM

Meloxicam 1.5 mg/ml oral suspension for dogs
Assessed clinical scopeDog · Full labelled canine oral scope for alleviation of inflammation and pain in acute and chronic musculoskeletal disorders · By mouth
Care settingVeterinary-prescribed home oral NSAID treatment after patient screening, with measured response, toxicity surveillance and periodic reassessment for longer courses
vetman score 7.9/10 Good
Evidence confidence: High Georgia: Yes, veterinary · № 300-11; 320-11; 321-11 · Verified on 20 Oct 2026

A well-supported, precisely dosed once-daily oral NSAID for the labelled canine acute and chronic musculoskeletal scope. Its strong regulatory and efficacy foundation is balanced by the established gastrointestinal, renal and hepatic risks of systemic NSAID therapy; careful patient selection, lowest-effective-dose use, monitoring and multimodal rehabilitation remain essential.

Regulatory and scientific credibility8.5/10

The exact dog-only 1.5 mg/ml suspension has a valid Spanish authorisation in the EU Union Product Database, current official product information, and active Georgian veterinary registrations for 10, 25 and 125 ml packs. It is an Article 13(1) generic with a clearly identified marketing-authorisation holder and manufacturing site; the older GB authorisation has expired and is not counted as current.

Clinical efficacy8.5/10

Randomized placebo-controlled and comparator trials support clinically meaningful improvement in canine osteoarthritis and chronic musculoskeletal pain with oral meloxicam, including the labelled 0.2 mg/kg loading and 0.1 mg/kg once-daily maintenance regimen. Evidence is mature and consistent, while individual response still requires objective reassessment and multimodal management.

Safety and tolerability6.5/10

Canine meloxicam safety is well characterised, but gastrointestinal ulceration or bleeding, renal injury and hepatic reactions can be serious or rarely fatal. Risk rises with dehydration, hypovolaemia, hypotension, organ disease, overdose, prolonged exposure or overlap with another NSAID, corticosteroid or nephrotoxic treatment.

Clinical practicality8.5/10

Once-daily dosing, a ready 1.5 mg/ml suspension, food administration and the supplied kg-calibrated syringe make home delivery and weight-based measurement straightforward. The bottle must be shaken, day-one volume doubled correctly, response checked within 3-4 days, and longer treatment coupled to risk-based clinical and laboratory monitoring.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • This assessment is for exact ADOCAM 1.5 mg/ml oral suspension in dogs and its full labelled acute/chronic musculoskeletal scope. It does not transfer to cats, another concentration, an injectable product or an unidentified meloxicam presentation.
  • Shake well and give with food. Give 0.2 mg/kg once on day 1, then 0.1 mg/kg every 24 hours from day 2. The supplied kg-calibrated syringe measures the maintenance volume, so the day-one volume is twice the marked body-weight dose.
  • Clinical response is usually expected within 3-4 days. If no improvement is evident, stop no later than day 10 and reassess the diagnosis, pain source, adherence and treatment plan rather than continuing automatically.
  • Do not use with gastrointestinal ulceration or bleeding, impaired hepatic, cardiac or renal function, haemorrhagic disorders, or known hypersensitivity to meloxicam or another NSAID.
  • Avoid in dehydrated, hypovolaemic or hypotensive dogs because renal toxicity risk is increased. Correct perfusion and hydration deficits and assess renal risk before treatment.
  • Do not combine with another NSAID or glucocorticoid. After prior anti-inflammatory treatment, use a veterinarian-determined washout of at least 24 hours and extend it when the previous product pharmacology requires.
  • Use particular caution with anticoagulants, diuretics, ACE inhibitors, aminoglycosides and other potentially nephrotoxic or highly protein-bound medicines; review the complete medication and anaesthetic plan before starting.
  • Stop and reassess promptly for anorexia, apathy, vomiting, diarrhoea, melaena or other faecal blood, altered drinking/urination, jaundice or suspected NSAID toxicity. Adverse reactions are usually early but may rarely be serious or fatal.
  • Do not use during pregnancy or lactation or in dogs younger than 6 weeks. Safety has not been established in these groups.
  • Use the lowest effective dose for the shortest necessary duration. For chronic treatment, document baseline and interval renal, hepatic and haematologic assessment, objective pain/function response, body weight and concurrent multimodal measures.
Assessment sources
  1. ADOCAM EU UPD2024
  2. ADOCAM GE register2026
  3. VMD leaflet / EU UPD2022
  4. FDA Metacam label2023
  5. Meloxicam canine OA placebo trial2000
  6. Canine OA meloxicam multicentre RCT2004
  7. Meloxicam-mavacoxib OA trial2014
  8. AAHA Pain Guidelines 20222022
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Meloxicam1.5 mg/ml
Formulation Type
Suspension
Administration route
By mouth
Manufacturer
aniMedica Herstellungs GmbH · Germany
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ადოკამი 1.5 მგ/მლ
№ 300-11; 320-11; 321-11
Verified on: 20 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Dog
WeightLoading · By mouthMaintenance · By mouth
Any weight 0.2 mg/kg 0.1 mg/kg
  • Loading · By mouth (once on day 1): Shake well and administer mixed with food. The supplied kg-scaled syringe measures the 0.1 mg/kg maintenance volume; on day 1 give twice that volume. Clinical response is usually seen within 3-4 days; stop by day 10 if there is no improvement. Do not use during pregnancy or lactation, under 6 weeks, or with gastrointestinal, hepatic, cardiac, renal or haemorrhagic disorders. Avoid in dehydrated, hypovolaemic or hypotensive animals. Do not combine with another NSAID or a glucocorticoid; observe an appropriate washout of at least 24 hours where applicable. Stop and seek veterinary advice if anorexia, apathy, vomiting, diarrhoea or faecal blood occurs; reactions may rarely be serious or fatal.
  • Maintenance · By mouth (once daily at 24-hour intervals from day 2): Shake well and administer mixed with food. The supplied kg-scaled syringe measures the 0.1 mg/kg maintenance volume; on day 1 give twice that volume. Clinical response is usually seen within 3-4 days; stop by day 10 if there is no improvement. Do not use during pregnancy or lactation, under 6 weeks, or with gastrointestinal, hepatic, cardiac, renal or haemorrhagic disorders. Avoid in dehydrated, hypovolaemic or hypotensive animals. Do not combine with another NSAID or a glucocorticoid; observe an appropriate washout of at least 24 hours where applicable. Stop and seek veterinary advice if anorexia, apathy, vomiting, diarrhoea or faecal blood occurs; reactions may rarely be serious or fatal.
Source:
VMD leaflet / EU UPD
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Adocam 1.5 mg/ml oral suspension for dogs - Official Product Information
UK Veterinary Medicines Directorate / EU Union Product Database, 2022
Active substance doses, with sources
Active substance Meloxicam
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.1 mg/kg Dog Maintenance By mouth once daily
Source: EMA UPD SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
MELOXICAM Bioveta 1.5 mg/ml oral suspension for dogs - SPC (Czech Republic)
EU Union Product Database, 2026
0.2 mg/kg Dog Inflammation Subcutaneous once
Norbrook Meloxicam, VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Norbrook Meloxicam 5 mg/ml Solution for Injection for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024
0.2 mg/kg Dog Loading By mouth once, day 1
Source: EMA UPD SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
MELOXICAM Bioveta 1.5 mg/ml oral suspension for dogs - SPC (Czech Republic)
EU Union Product Database, 2026
0.2 mg/kg Dog Inflammation
Premedication
 Intravenous once
Norbrook Meloxicam, VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Norbrook Meloxicam 5 mg/ml Solution for Injection for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024
0.3 mg/kg Cat Inflammation Subcutaneous once
Norbrook Meloxicam, VMD SPC 2024
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Norbrook Meloxicam 5 mg/ml Solution for Injection for Dogs and Cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2024

Known Contraindications

  • Critical
    Do not use in animals suffering from... impaired hepatic, cardiac or renal function
    Sources: VMD SPC · VMD
  • Critical
    Do not use meloxicam in animals with impaired cardiac function.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals suffering from... haemorrhagic disorders.
    Sources: VMD SPC · VMD
  • Critical
    Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.
    Sources: VMD SPC · VMD
  • Critical
    Hepatic impairment is a contraindication.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage
    Sources: VMD SPC · VMD
  • Critical
    Do not use meloxicam during pregnancy.
    Sources: VMD SPC · VMD
  • Critical
    Do not use meloxicam during lactation.
    Sources: VMD SPC · VMD
  • Critical
    Known hypersensitivity to meloxicam or any excipient is a contraindication.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in animals less than 6 weeks of age
    Sources: VMD SPC · VMD
  • Warning
    Avoid use in any dehydrated, hypovolaemic or hypotensive animal
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Contraindicated Meloxicam + Prednisolone
    Concomitant use of corticosteroids and non-steroidal anti-inflammatory drugs can worsen gastrointestinal ulceration.
    Recommendation: Do not administer together. Observe an appropriate washout period when switching and monitor for melena, vomiting, and reduced appetite.
    Sources: Product label
  • Contraindicated Meloxicam + Robenacoxib
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Meloxicam + Carprofen
    Do not give other non-steroidal anti-inflammatory drugs or glucocorticoids concurrently with carprofen or within 24 hours of treatment because gastrointestinal ulceration or perforation may occur.
    Recommendation: Consider appropriate washout times when switching from one NSAID to another or when switching from corticosteroid use to NSAID use.
    Sources: FDA
  • Major warning Meloxicam + Dexamethasone
    The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration.
    Recommendation: Avoid concurrent administration. Observe an appropriate washout period when switching. If both are essential, provide gastroprotection and monitor gastrointestinal signs closely.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (4 more) Hide additional products

Same therapeutic group 4

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 20 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗